clinical trial · NCT00092027
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
Organon and Co·phase3·completed·n = 454
Postmenopausal OsteoporosisMK0217, alendronate sodium/Duration of Treatment: 6 monthsComparator: placebo / Duration of Treatment: 6 months
brief summary
This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.
started
Mar 19, 2003
primary completion
Mar 15, 2004
completion
Mar 15, 2004
last updated
Aug 14, 2024
official title
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol